165 related articles for article (PubMed ID: 32666019)
41. Evaluation of management of patients with postoperative permanent hypoparathyroidism. How close are we to the targets?
Onder CE; Kuskonmaz SM; Koc G; Firat SN; Omma T; Culha C
Minerva Endocrinol (Torino); 2023 Mar; 48(1):12-18. PubMed ID: 33269571
[TBL] [Abstract][Full Text] [Related]
42. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism.
Sikjaer T; Moser E; Rolighed L; Underbjerg L; Bislev LS; Mosekilde L; Rejnmark L
J Bone Miner Res; 2016 Jul; 31(7):1440-8. PubMed ID: 26865527
[TBL] [Abstract][Full Text] [Related]
43. [Not Available].
Espiard S; Vantyghem MC; Desailloud R
Ann Endocrinol (Paris); 2017 Oct; 78 Suppl 1():S1-S10. PubMed ID: 29157484
[TBL] [Abstract][Full Text] [Related]
44. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults.
Bollerslev J; Rejnmark L; Marcocci C; Shoback DM; Sitges-Serra A; van Biesen W; Dekkers OM;
Eur J Endocrinol; 2015 Aug; 173(2):G1-20. PubMed ID: 26160136
[TBL] [Abstract][Full Text] [Related]
45. The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark: A Nationwide Case Finding Study.
Underbjerg L; Sikjaer T; Mosekilde L; Rejnmark L
J Bone Miner Res; 2015 Sep; 30(9):1738-44. PubMed ID: 25753591
[TBL] [Abstract][Full Text] [Related]
46. Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections.
Underbjerg L; Sikjaer T; Mosekilde L; Rejnmark L
J Bone Miner Res; 2014 Nov; 29(11):2504-10. PubMed ID: 24806578
[TBL] [Abstract][Full Text] [Related]
47. PTH treatment in hypoparathyroidism.
Sikjaer T; Rejnmark L; Mosekilde L
Curr Drug Saf; 2011 Apr; 6(2):89-99. PubMed ID: 21524246
[TBL] [Abstract][Full Text] [Related]
48. Dental Findings in Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism: A Systematic Review.
Hejlesen J; Underbjerg L; Gjørup H; Bloch-Zupan A; Sikjaer T; Rejnmark L; Haubek D
Front Physiol; 2018; 9():701. PubMed ID: 29971010
[No Abstract] [Full Text] [Related]
49. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
50. Development and Psychometric Evaluation of the Hypoglycemia Perspectives Questionnaire in Patients with Type 2 Diabetes Mellitus.
Kawata AK; Wilson H; Ong SH; Kulich K; Coyne K
Patient; 2016 Oct; 9(5):395-407. PubMed ID: 26970976
[TBL] [Abstract][Full Text] [Related]
51. Defining the Characteristics of Chronic Hypoparathyroidism Not Adequately Controlled on Conventional Therapy: Consensus Findings of Three European Delphi Panels.
Iqbal K; Dass N; Gip C; Vila J; Rylands AJ; Marelli C
Adv Ther; 2019 Nov; 36(11):3007-3016. PubMed ID: 31587144
[TBL] [Abstract][Full Text] [Related]
52. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
53. Bone mineral density in patients with chronic hypoparathyroidism.
Abugassa S; Nordenström J; Eriksson S; Sjödén G
J Clin Endocrinol Metab; 1993 Jun; 76(6):1617-21. PubMed ID: 8501170
[TBL] [Abstract][Full Text] [Related]
54. PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.
Santonati A; Palermo A; Maddaloni E; Bosco D; Spada A; Grimaldi F; Raggiunti B; Volpe R; Manfrini S; Vescini F;
J Clin Endocrinol Metab; 2015 Sep; 100(9):3590-7. PubMed ID: 26196949
[TBL] [Abstract][Full Text] [Related]
55. From hypocalcemia to hypercalcemia-an unusual clinical presentation of a patient with permanent postsurgical hypoparathyroidism.
Sundaresh V; Levine SN
J Clin Endocrinol Metab; 2015 Jan; 100(1):21-4. PubMed ID: 25303492
[TBL] [Abstract][Full Text] [Related]
56. Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism.
García-Pascual L; Barahona MJ; Perea V; Simó R
J Clin Endocrinol Metab; 2017 Jan; 102(1):259-266. PubMed ID: 27813709
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease.
Leidig-Bruckner G; Bruckner T; Raue F; Frank-Raue K
Horm Metab Res; 2016 Dec; 48(12):806-813. PubMed ID: 27813050
[TBL] [Abstract][Full Text] [Related]
58. Pattern of bone mineral density in patients with sporadic idiopathic hypoparathyroidism.
Laway BA; Goswami R; Singh N; Gupta N; Seith A
Clin Endocrinol (Oxf); 2006 Apr; 64(4):405-9. PubMed ID: 16584512
[TBL] [Abstract][Full Text] [Related]
59. Psychometric Properties of the Short Form of the Health Practices Questionnaire-II Chinese Version.
Wang LH; Chang YP; Chou HF; Doerzbacher M; Lin HS
J Obstet Gynecol Neonatal Nurs; 2019 Mar; 48(2):205-215. PubMed ID: 30664841
[TBL] [Abstract][Full Text] [Related]
60. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D.
Collins MT; Lindsay JR; Jain A; Kelly MH; Cutler CM; Weinstein LS; Liu J; Fedarko NS; Winer KK
J Bone Miner Res; 2005 Nov; 20(11):1944-50. PubMed ID: 16234967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
